Inogen Inc (INGN) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS

Inogen Inc (NASDAQ:INGN) announced its earnings results on Tuesday. The medical technology company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.15. The business had revenue of $52.50 million for the quarter, compared to the consensus estimate of $49.06 million. Inogen had a net margin of 7.70% and a return on equity of 9.59%. Inogen’s quarterly revenue was up 22.1% on a year-over-year basis. During the same period last year, the firm posted $0.12 earnings per share.

Shares of Inogen (NASDAQ:INGN) traded up 3.00% on Friday, hitting $84.15. 188,957 shares of the stock traded hands. The firm has a 50 day moving average price of $80.32 and a 200 day moving average price of $70.30. Inogen has a 52-week low of $44.26 and a 52-week high of $88.61. The firm has a market cap of $1.73 billion, a PE ratio of 75.27 and a beta of 1.07.

Earnings History for Inogen (NASDAQ:INGN)

INGN has been the topic of several research reports. Zacks Investment Research downgraded shares of Inogen from a “strong-buy” rating to a “hold” rating in a research note on Monday, February 6th. Needham & Company LLC lifted their price target on shares of Inogen from $78.00 to $83.00 and gave the stock a “strong-buy” rating in a research note on Wednesday, March 1st. Stifel Nicolaus lifted their price target on shares of Inogen to $65.00 in a research note on Wednesday, March 1st. JPMorgan Chase & Co. set a $78.00 price target on shares of Inogen and gave the stock a “buy” rating in a research note on Wednesday, March 1st. Finally, TheStreet raised shares of Inogen from a “c” rating to a “b-” rating in a research note on Tuesday, February 28th. Two equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $80.33.

In other Inogen news, EVP Matt Scribner sold 2,500 shares of the business’s stock in a transaction on Wednesday, March 15th. The stock was sold at an average price of $73.85, for a total transaction of $184,625.00. Following the transaction, the executive vice president now owns 4,833 shares of the company’s stock, valued at $356,917.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Byron Myers sold 10,000 shares of the business’s stock in a transaction on Monday, April 24th. The stock was sold at an average price of $80.00, for a total value of $800,000.00. Following the transaction, the executive vice president now directly owns 45,185 shares in the company, valued at approximately $3,614,800. The disclosure for this sale can be found here. Insiders have sold 25,416 shares of company stock worth $1,990,465 in the last three months. 5.18% of the stock is currently owned by corporate insiders.

A number of large investors have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. acquired a new stake in Inogen during the first quarter worth approximately $109,000. Victory Capital Management Inc. increased its stake in Inogen by 36.1% in the first quarter. Victory Capital Management Inc. now owns 1,729 shares of the medical technology company’s stock worth $134,000 after buying an additional 459 shares in the last quarter. State of Alaska Department of Revenue increased its stake in Inogen by 4.1% in the first quarter. State of Alaska Department of Revenue now owns 1,790 shares of the medical technology company’s stock worth $138,000 after buying an additional 70 shares in the last quarter. Municipal Employees Retirement System of Michigan increased its stake in Inogen by 1.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 3,220 shares of the medical technology company’s stock worth $193,000 after buying an additional 50 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in Inogen during the first quarter worth approximately $203,000.

ILLEGAL ACTIVITY NOTICE: “Inogen Inc (INGN) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS” was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are viewing this piece on another domain, it was copied illegally and republished in violation of United States & international copyright & trademark law. The correct version of this piece can be accessed at https://www.chaffeybreeze.com/2017/05/20/inogen-inc-ingn-releases-quarterly-earnings-results-updated.html.

About Inogen

Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.

12 Month Chart for NASDAQ:INGN

Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply